Peter Pitts

Peter Pitts is President and co-founder of the Center for Medicine in the Public Interest. He also serves as a Visiting Professor at University of Paris School of Medicine. Pitts lives in New York City

Professor Pitts is a former member of the United States Senior Executive Service and Associate Commissioner of the US Food & Drug Administration where he served as senior communications and policy adviser to the Commissioner. He supervised FDA's Office of Public Affairs, Office of the Ombudsman, Office of Special Health Issues, Office of Executive Secretariat, and Advisory Committee Oversight and Management. He served on the agency’s obesity working group and counterfeit drug taskforce.

He is a member of the Council for International Organizations of Medical Sciences (CIOMS) Expert Working Group to help advance patient involvement in the development and safe use of medicines. (CIOMS is an international, non-governmental, non-profit organization established jointly by WHO and UNESCO in 1949.) He is the lead author of many professional peer reviewed publications including the Lancet, Therapeutic Innovation and Regulatory Science, and Nature Biotechnology. He is an Associate Editor of Therapeutic Innovation & Regulatory Science (the official DIA journal), a member of the External Advisory Board, IMS Institute for Healthcare Informatics in Asia, Executive Advisory Board, the Galien Foundation, Editorial Advisory Board, Food and Drug Policy Forum, Advisory Board, Journal of Commercial Biotechnology and a member of the Editorial Advisory Board of The Patient Magazine.

His comments and commentaries on health care policy issues regularly appear in The New York Times, The Los Angeles Times, The Washington Post, The Wall Street Journal, The Financial Times, Health Affairs, Time, Newsweek, The Boston Globe, The Washington Times, The Chicago Tribune, The San Francisco Examiner, Investor’s Business Daily, The Baltimore Sun, The Economist, The Lancet, Nature Biotechnology, BioCentury, The Journal of Commercial Biotechnology, the BBC World Service, Fox News, CNBC, Bloomberg, The PBS NewsHour, NBC Dateline, Sky News, La Stampa. L’Opinion, The Daily Show with John Stewart, among others.

He has given healthcare policy lectures throughout Europe, Canada, and the United States, as well as in Russia, China, Hong Kong, Taiwan, India, the Philippines, Malaysia, Saudi Arabia, Lebanon, Oman, Israel, Turkey, The United Arab Emirates, Kuwait, Qatar, Jordan, Kenya, South Africa, Egypt, Algeria, Ukraine, Thailand, Japan, Brazil, Mexico, Vietnam, Indonesia, Singapore, Panama, Costa Rica, Argentina, and Columbia.  

His new book, The Next Normal discusses how we can apply the lessons learned from COVID-19 to advance other areas of healthcare. He is also the author of two other books on advancing America’s health, The Value Equation and Commonsense Healthcare Policy for Commonsense Americans. He is also the author of Become Strategic or Die, widely recognized as a cutting edge study of how leadership, in order to be successful over the long term, must be combined with strategic vision and ethical practice. He is the editor of Coincidence or Crisis, a discussion of global prescription medicine counterfeiting and Physician Disempowerment: A Transatlantic Malaise.

He has also served as an adjunct professor at Indiana University’s School of Public and Environmental Affairs and Butler University.





 

 
Sign Up for Our Email Newsletter

RECENT NEWS

New Report Demonstrates How Hospitals, Pharmacies & PBMs Exploit the Federal 340B Drug Program to the Harm of Disadvantaged Patients
  • CMPI
  • 09/09/2022 12:00 AM

New Report Demonstrates How Hospitals, Pharmacies & PBMs Exploit the Federal 340B Drug Program to the Harm of Disadvantaged Patients

Nation’s largest hospitals, pharmacy benefit managers (PBMs), and pharmacies abuse drug discount program to pocket saving...  Read more

Peter Pitts on CDC reorganization proposal

Peter Pitts on CDC reorganization proposal

Peter Pitts joins NEWSY to discuss proposed CDC changes...  Read more

Why the FTC is Investigating Pharmacy Benefit Managers

Why the FTC is Investigating Pharmacy Benefit Managers

In money matters, U.S. regulators are investigating claims by PBMs who say they save you money on prescriptions....  Read more

DRUGWONKS BLOG